Immunological responses to injury and grafting in the central nervous system of nonhuman primates

Author(s): Bakay RA, Boyer KL, Freed CR, Ansari AA

Abstract

Allogeneic transplantation for the therapy of human Parkinson's disease is being considered as a viable approach at several clinical centers worldwide. As an attempt to understand the basic biology of central nervous system (CNS) transplantation, our laboratory has developed an experimental nonhuman primate model for human Parkinson's disease and carried out preliminary studies directed at evaluating the potential pathology at the graft site. In addition, studies have been conducted to examine whether such transplantation procedures lead to specific and/or nonspecific immunologic sensitization of the host or results in generalized immunosuppression. Groups of rhesus macaques (Macaca mulatta) were either controls operated (n = 6), autografted with adrenal medullary and peripheral nerve tissue (n = 3), or allografted with fetal mesencephalic tissue (n = 6). Immunohistological studies demonstrated the presence of mononuclear cell infiltrates as early as 1 wk and up to 1 yr postoperatively, although the frequency of the infiltrating cells declined with time. The infiltrates consisted of variable numbers of cells which express CD2+, CD3+, CD4+, CD8+, CD19+, CD22+, CD25+, and CD68+. There appeared to be no difference in the frequency, kinetics, or phenotype of the infiltrating cells in operative controls compared with recipients of auto- or allografts. Tissue sections obtained postoperatively showed low levels of major histocompatibility complex (MHC) Class I antigens and no detectable level of MHC-Class II antigens in neural tissue. A small aliquot of tissue from the operative site was placed in vitro with media containing interleukin-2 (IL-2), which led to the exudation and growth of mononuclear cells that were predominantly CD4+ cells. Phenotypic studies of peripheral blood mononuclear cells (PBMC) from operative controls, auto- and allograft recipient monkeys performed at varying time periods postoperatively failed to show differences in the frequencies of subsets of T-cells, B-cells, NK-cells, or monocytes. Studies on aliquots of the same PBMC failed to show major functional differences in NK-cells, LAK cells, or response to polyclonal mitogens. Finally, recipients of allogeneic mesencephalic grafts failed to show evidence of donor-specific humoral or cellular sensitization. These data indicate that transplantation of autograft adrenal or allograft fetal mesencephalic tissues in the CNS of nonhuman primate did not induce detectable donor-specific sensitization nor nonspecific immunosuppression.

Similar Articles

Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease

Author(s): Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL

Alterations of T-lymphocyte populations in Parkinson disease

Author(s): Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T

Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism

Author(s): Bas J, Calopa M, Mestre M, Molleví DG, Cutillas B, et al.

Apoptosis of peripheral blood lymphocytes in Parkinson patients

Author(s): Calopa M, Bas J, Callén A, Mestre M

The ABC of the blood-brain barrier - regulation of drug efflux pumps

Author(s): Mahringer A, Ott M, Reimold I, Reichel V, Fricker G

Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy

Author(s): van Vliet EA, da Costa Araújo S, Redeker S, van Schaik R, Aronica E, et al.

Blood-brain barrier disruption in multiple sclerosis

Author(s): Minagar A, Alexander JS

The role of neuroinflammation on the pathogenesis of Parkinson's disease

Author(s): Chung YC, Ko HW, Bok E, Park ES, Huh SH, et al.

Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA

Author(s): Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, et al.

Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9

Author(s): Koronyo-Hamaoui M, Ko MK, Koronyo Y, Azoulay D, Seksenyan A, et al.

Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells

Author(s): Reynolds AD, Stone DK, Mosley RL, Gendelman HE

Leptin and ghrelin concentrations and weight loss in Parkinson's disease

Author(s): Fiszer U, Michałowska M, Baranowska B, Wolińska-Witort E, Jeske W, et al.

Innate and adaptive immunity for the pathobiology of Parkinson's disease

Author(s): Stone DK, Reynolds AD, Mosley RL, Gendelman HE

Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression

Author(s): Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, et al.

Anti-melanin antibodies are increased in sera in Parkinson's disease

Author(s): Double KL, Rowe DB, Carew-Jones FM, Hayes M, Chan DK, et al.

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

Author(s): Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al.

Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease

Author(s): Johnston LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, et al.

α-Synuclein and dopamine at the crossroads of Parkinson's disease

Author(s): Venda LL, Cragg SJ, Buchman VL, Wade-Martins R

Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease

Author(s): Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, et al.

T-cells in Alzheimer's disease

Author(s): Town T, Tan J, Flavell RA, Mullan M